Results 61 to 70 of about 2,437,081 (240)

Eosinophilic bronchitis, eosinophilic granuloma, and eosinophilic bronchopneumopathy in 75 dogs (2006-2016). [PDF]

, 2019
BackgroundEosinophilic lung disease is a poorly understood inflammatory airway disease that results in substantial morbidity.ObjectiveTo describe clinical findings in dogs with eosinophilic lung disease defined on the basis of radiographic, bronchoscopic,
Dear, Jonathan D, Hulsebosch, Sean E, Johnson, Eric G, Johnson, Lynelle R, Vernau, William   +4 more
core   +1 more source

Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC)

Cells
Hypereosinophilic syndrome (HES) encompasses a heterogeneous and complex group of different subtypes within the wider group of hypereosinophilic disorders.
M. Caminati, L. Brussino, Matilde Carlucci, Palma Carlucci, Lucia Federica Carpagnano, C. Caruso, L. Cosmi, Simona D’Amore, S. D. Del Giacco, Aikaterini Detoraki, Mario Di Gioacchino, A. Matucci, I. Mormile, F. Granata, G. Guarnieri, M. Krampera, M. Maule, E. Nettis, Stefania Nicola, S. Noviello, F. Pane, C. Papayannidis, P. Parronchi, G. Pelaia, E. Ridolo, F. W. Rossi, G. Senna, Massimo Triggiani, Angelo Vacca, E. Vivarelli, A. Vultaggio, A. de Paulis   +31 more
semanticscholar   +1 more source

Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution

Cytometry. Part B, Clinical cytometry, 2020
Lymphocytic variant of hypereosinophilic syndrome (L‐HES) is a subtype of HES driven by cytokines produced by clonal T‐cells. Due to the rarity of its occurrence and challenges in diagnosis, this subtype of HES is under recognized.
Z. Hu, Wei Wang, B. Thakral, Zhining Chen, Z. Estrov, C. Bueso-Ramos, S. Verstovsek, L. Medeiros, Sa A. Wang   +8 more
semanticscholar   +1 more source

Medical algorithm: Diagnosis and treatment of hypereosinophilic syndrome

Allergy. European Journal of Allergy and Clinical Immunology, 2020
Hypereosinophilic syndrome (HES) is a group of rare disorders characterized by persistently elevated eosinophil count and eosinophil-mediated organ damage. The most frequent symptoms are cutaneous (e.g. urticaria, angioedema) and respiratory (e.g. asthma,
B. Schuster, A. Zink, K. Eyerich
semanticscholar   +1 more source

Hypereosinophilic Syndrome: Contemporary Approaches to Molecular-Genetic Diagnostics and Gene-Engineered Biologic Therapy

Медицина и биотехнологии
Introduction. In recent years, there has been a growing interest among researchers in conditions associated with hypereosinophilia and the therapeutic potential of genetically engineered biological agents.
Larisa A. Balykova, Anna V. Krasnopolskaya, Marina V. Shirmankina, Diva Augusta T. Mendes, Anastasia M. Khanina   +4 more
doaj   +1 more source

Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]

, 2008
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad, Daley, George, Gray, Nathanael, KURIYAN, John, Seeliger, Markus   +4 more
core   +1 more source

Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment

JAAD Case Reports, 2020
IL: interleukin INTRODUCTION Hypereosinophilic syndromes are rare disorders defined by persistent peripheral eosinophilia (absolute eosinophil count[1.53 10/L) plus evidence of organ involvement.
Jill K Wieser, G. Kuehn, J. Prezzano, Elizabeth H. Cusick, Julia D. Stiegler, G. Scott, J. Liesveld, L. Beck   +7 more
semanticscholar   +1 more source

Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma

Respiratory Research
Conventional immunosuppressants are ineffective for the management of EGPA-related asthma. Tezepelumab is a human monoclonal antibody that inhibits thymic stromal lymphopoietin (TLSP) that has proven efficacy in several phase 3 studies for the treatment ...
Nina Vincent-Galtié, Quentin Marquant, Emilie Catherinot, Felix Ackermann, Antoine Magnan, Colas Tcherakian, Matthieu Groh   +6 more
doaj   +1 more source

Right sided heart failure secondary to hypereosinophilic cardiomyopathy – clinical manifestation and diagnostic pathway

Radiology Case Reports, 2020
Hypereosinophilic cardiomyopathy is a rare restrictive cardiomyopathy which often presents with left-sided heart failure. We present an interesting case of a 58-year-old male patient with known hypereosinophillic syndrome who had presented with ...
Jennie Han, BA, BM BCh, Mohammad Ramtoola, MB ChB, Muhammad Shahzad, MBBS, Kenneth Okonkwo, MBBS, Nadeem Attar, MBBS   +4 more
doaj   +1 more source

Benralizumab for PDGFRA‐Negative Hypereosinophilic Syndrome

New England Journal of Medicine, 2019
Background Hypereosinophilic syndrome is a group of diseases defined by marked eosinophilia in blood or tissue and eosinophil‐related clinical manifestations.
F. Kuang, Fanny Legrand, M. Makiya, JeanAnne M Ware, L. Wetzler, Thomas Brown, Tamika Magee, Brent Piligian, Pryscilla Yoon, J. Ellis, Xiaoping Sun, Sandhya R. Panch, Astin S Powers, H. Alao, Sheila Kumar, Martha M. Quezado, Li Yan, N. Lee, Roland Kolbeck, P. Newbold, M. Goldman, Michael P Fay, P. Khoury, Irina Maric, A. Klion   +24 more
semanticscholar   +1 more source